Page last updated: 2024-11-06
guanazodine
Description
Guanazodine is a potent antihypertensive agent that acts as a peripheral postsynaptic alpha-adrenergic blocker. It is structurally related to guanethidine, but it differs in its chemical structure and pharmacological properties. Guanazodine is synthesized by a multi-step process involving the condensation of 2-aminobenzimidazole with 1,4-dichlorobutane. Guanazodine has been shown to effectively lower blood pressure by reducing peripheral vascular resistance. It is studied due to its potential therapeutic applications in the treatment of hypertension and other cardiovascular conditions. However, guanazodine has been largely superseded by other antihypertensive agents due to its potential adverse effects, including orthostatic hypotension, diarrhea, and a risk of developing tachyphylaxis. Despite its limited clinical use, guanazodine remains a valuable tool for research into the mechanisms of adrenergic neurotransmission and the development of new antihypertensive drugs.'
guanazodine: synonyms EGYT-739 & Sanegyt (Sanegit) refers to sulfate; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 36054 |
| CHEMBL ID | 2008565 |
| CHEBI ID | 134828 |
| SCHEMBL ID | 310388 |
| SCHEMBL ID | 11730768 |
| MeSH ID | M0062238 |
Synonyms (29)
| Synonym |
|---|
| NCI60_002569 |
| 1-azacyclooct-2-ylmethyl guanidine |
| guanidine, 1-azacyclooct-2-ylmethyl- |
| brn 0473717 |
| guanazodine [inn] |
| ((octahydro-2-azocinyl)methyl)guanidine |
| 32059-15-7 |
| D07169 |
| guanazodine (inn) |
| guanazodine |
| CHEBI:134828 |
| 2-(azocan-2-ylmethyl)guanidine |
| AKOS006273696 |
| guanidine, ((octahydro-2-azocinyl)methyl)- |
| 5-22-08-00154 (beilstein handbook reference) |
| unii-7n05kq38yi |
| 7n05kq38yi , |
| CHEMBL2008565 |
| guanazodine [who-dd] |
| 1-azacyclooct-2-ylmethylguanidine |
| guanazodine [mi] |
| .alpha.-guanidinomethylheptamethylenimine |
| SCHEMBL310388 |
| SCHEMBL11730768 |
| Q5613575 |
| DB13604 |
| guanidine, [(octahydro-2-azocinyl)methyl]-; alpha-guanidinomethylheptamethylenimine |
| DTXSID30953934 |
| guanidine, [(octahydro-2-azocinyl)methyl]-; -guanidinomethylheptamethylenimine |
Drug Classes (1)
| Class | Description |
|---|
| guanidines | Any organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |